CTLA4 and neoplasm: Blocking these checkpoints with monoclonal antibodies—such as ipilimumab (anti-CTLA-4) and nivolumab or atezolizumab (anti-PD-1/PD-L1)—has proven effective in restoring cytotoxic responses and promoting tumor cell death [49].